摘要
在过去的15年里,分子生物学的进步暴露了弥漫性大B细胞淋巴瘤(DLBCL)的基因和病理生理异质性。患者亚群已被确定,其中当前化学免疫治疗可能不是有效的,如激活B细胞亚型(ABC)。在这次报告中,我们对两个主要DLBCL亚型之间的差异(生发中心B细胞[GCB]和ABC)进行了深入的研究,特别侧重在他们的不同的遗传特性,活跃肿瘤途径和病理特征。我们还讨论了建立桥梁从替补席到通过转化研究病人护理的前沿,包括使用免疫组织化学和基因分析对DLBCL患者进行分类和目前的临床试验数据与新的可能的靶向治疗这两种亚型的DLBCL患者。我们希望临床医生使用该报告作为一种工具来更好地理解在日常实践中看到两个较为普遍DLBCL亚型的复杂性和在当前和即将到来的新的治疗选择中更新自己的知识,以潜在地改变这个群体的结果。
关键词: 激活B细胞亚型,临床试验,弥漫性大B细胞淋巴瘤,生发中心B细胞,基因表达分析,治疗。
图形摘要
Current Cancer Drug Targets
Title:A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
Volume: 16 Issue: 4
Author(s): Jose D. Sandoval-Sus, Julio Chavez, Samir Dalia
Affiliation:
关键词: 激活B细胞亚型,临床试验,弥漫性大B细胞淋巴瘤,生发中心B细胞,基因表达分析,治疗。
摘要: In the past 15 years, advances in molecular biology have exposed the genetic and physiopathologic heterogeneity of diffuse large B-cell lymphoma (DLBCL). Subsets of patients have been identified in which current chemoimmunotherapies may not be as efficacious, such as the activated B-cell subtype (ABC). In this review, we present an in-depth study of the differences between the two main DLBCL subsets (germinal center B cell [GCB] and ABC), focusing specifically on their different genetic features, active tumoral pathways, and pathologic features. We also discuss the bridges that have been built from the bench to the forefront of patient care through translational research, including the use of immunohistochemistry versus gene profiling to categorize patients with DLBCL and current clinical trial data pertaining to new possible targeted therapies for patients with these two subtypes of DLBCL. We hope that clinicians use this review as a tool to better understand the complexity of the two more prevalent DLBCL subtypes seen in the day to day practice and update their knowledge in both current and upcoming novel treatment options that can potentially change the outcomes of this population.
Export Options
About this article
Cite this article as:
Jose D. Sandoval-Sus, Julio Chavez, Samir Dalia , A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review, Current Cancer Drug Targets 2016; 16 (4) . https://dx.doi.org/10.2174/1568009615666151030102539
DOI https://dx.doi.org/10.2174/1568009615666151030102539 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
Recent Patents on DNA & Gene Sequences Advances in Photodynamic Therapy Assisted by Electroporation
Current Drug Metabolism Role of miRNAs in Muscle Stem Cell Biology: Proliferation, Differentiation and Death
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Trichothecenes: Structure-Toxic Activity Relationships
Current Drug Metabolism Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Trypanocidal Activity of Nitroaromatic Prodrugs: Current Treatments and Future Perspectives
Current Topics in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Natural and Structure-based RXR Ligand Scaffolds and Their Functions
Current Topics in Medicinal Chemistry Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs Rational Drug Design of Antineoplastic Agents Using 3D-QSAR, Cheminformatic, and Virtual Screening Approaches
Current Medicinal Chemistry Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued)